Fernando A. Rivera, M.D.

  1. Internist
  1. Fairweather D, Bruno KA, Darakjian AA, Bruce BK, Gehin JM, Kotha A, Jain A, Peng Z, Hodge DO, Rozen TD, Munipalli B, Rivera FA, Malavet PA, Knight DRT. High overlap in patients diagnosed with hypermobile Ehlers-Danlos syndrome or hypermobile spectrum disorders with fibromyalgia and 40 self-reported symptoms and comorbidities. Front Med (Lausanne). 2023; 10:1096180 Epub 2023 Apr 25
    View PubMed
  2. Rivera FA, Munipalli B, Allman ME, Hodge DO, Wieczorek MA, Wang B, Abril A, Perlman A, Knight D, Bruce B. A retrospective analysis of the prevalence and impact of associated comorbidities on fibromyalgia outcomes in a tertiary care center. Front Med (Lausanne). 2023; 10:1301944 Epub 2024 Jan 15
    View PubMed
  3. Munipalli B, Strothers S, Rivera F, Malavet P, Mitri G, Abu Dabrh AM, Dawson NL. Association of Vitamin B12, Vitamin D, and Thyroid-Stimulating Hormone With Fatigue and Neurologic Symptoms in Patients With Fibromyalgia. Mayo Clin Proc Innov Qual Outcomes. 2022 Aug; 6 (4):381-387 Epub 2022 July 31
    View PubMed
  4. Diaz LA Jr, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, de la Fourchardiere C, Rivera F, Elez E, Le DT, Yoshino T, Zhong WY, Fogelman D, Marinello P, Andre T, KEYNOTE-177 Investigators. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022 May; 23 (5):659-670 Epub 2022 Apr 12
    View PubMed
  5. Munipalli B, Allman ME, Chauhan M, Niazi SK, Rivera F, Abril A, Wang B, Wieczorek MA, Hodge DO, Knight D, Perlman A, Abu Dabrh AM, Dudenkov D, Bruce BK. Depression: A Modifiable Risk Factor for Poor Outcomes in Fibromyalgia. J Prim Care Community Health. 2022 Jan-Dec; 13:21501319221120738.
    View PubMed
  6. Bruce BK, Allman ME, Rivera FA, Wang B, Berianu F, Butendieck RR, Calamia KT, Hines SL, Rummans TA, Niazi SK, Abril A. Intensive Multicomponent Fibromyalgia Treatment: A Translational Study to Evaluate Effectiveness in Routine Care Delivery. J Clin Rheumatol. 2021 Dec 1; 27 (8):e496-e500
    View PubMed
  7. Bruce BK, Allman ME, Rivera FA, Abril A, Gehin JM, Oliphant LM, Nordan LM, White LJ, Martinez D, Niazi SK. Opioid Use in Fibromyalgia Continues Despite Guidelines That Do Not Support Its Efficacy or Risk. J Clin Rheumatol. 2021 Aug 1; 27 (5):187-193
    View PubMed
  8. Malouff TD, TerKonda SP, Knight D, Abu Dabrh AM, Perlman AI, Munipalli B, Dudenkov DV, Heckman MG, White LJ, Wert KM, Pascual JM, Rivera FA, Shoaei MM, Leak MA, Harrell AC, Trifiletti DM, Buskirk SJ. Physician Satisfaction With Telemedicine During the COVID-19 Pandemic: The Mayo Clinic Florida Experience. Mayo Clin Proc Innov Qual Outcomes. 2021 Aug; 5 (4):771-782 Epub 2021 July 01
    View PubMed
  9. Pullen SJ, Rasmussen KG, Angstman ER, Rivera F, Mueller PS. The safety of electroconvulsive therapy in patients with prolonged QTc intervals on the electrocardiogram. J ECT. 2011 Sep; 27(3):192-200.
    View PubMed
  10. Rivera FA, Lapid MI, Sampson S, Mueller PS. Safety of electroconvulsive therapy in patients with a history of heart failure and decreased left ventricular systolic heart function. J ECT. 2011 Sep; 27(3):207-13.
    View PubMed
  11. Campo RE, Rosa I, Lichtenberger PN, Suarez G, Rivera FA, Jayaweera DT, Rodriguez AE, Wahlay NA, Kolber MA. Effect of class-specific therapy interruption on persistence of HIV type 1 antiretroviral resistance. AIDS Res Hum Retroviruses. 2003 Aug; 19(8):653-6.
    View PubMed
  12. Campo RE, Lichtenberger PN, Rosa I, Suarez G, Rivera FA, Rodriguez AE, Jayaweera DT, Wahlay NA, Kolber MA. Differences in the frequency of resistance to antiretroviral drug classes among human immunodeficiency virus type 1 clinical isolates. J Clin Microbiol. 2003 Jul; 41(7):3376-8.
    View PubMed